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Background: We tested whether apoptotic adipose-derived mesenchymal stem cells (A-ADMSCs) were superior to
healthy (H)-ADMSCs at attenuating organ damage and mortality in sepsis syndrome following cecal ligation and
puncture (CLP).
Methods: Adult male rats were categorized into group 1 (sham control), group 2 (CLP), group 3 [CLP + H-ADMSC
administered 0.5, 6, and 18 h after CLP], group 4 [CLP + A-ADMSC administered as per group 3].
Results: Circulating peak TNF-α level, at 6 h, was highest in groups 2 and 3, and higher in group 4 than group 1
(p < 0.0001). Immune reactivity (indicated by circulating and splenic helper-, cytoxic-, and regulatory-T cells) at
24 and 72 h exhibited the same pattern as TNF-α amongst the groups (all p < 0.0001). The mononuclear-cell early
and late apoptosis level and organ damage parameters of liver (AST, ALT), kidney (creatinine) and lung (arterial
oxygen saturation) also displayed a similar pattern to TNF-α levels (all p < 0.001). Protein levels of inflammatory
(TNF-α, MMP-9, NF-κB, ICAM-1), oxidative (oxidized protein) and apoptotic (Bax, caspase-3, PARP) biomarkers were
higher in groups 2 and 3 than group 1, whereas anti-apoptotic (Bcl-2) biomarker was lower in groups 2 and 3
than in group 1 but anti-oxidant (GR, GPx, HO-1, NQO-1) showed an opposite way of Bcl-2; these patterns were
reversed for group 4 (all p < 0.001). Mortality was highest in group 3 and higher in group 2 than group 4 than
group 1 (all p < 0.001).
Conclusions: A-ADMSC therapy protected major organs from damage and improved prognosis in rats with
sepsis syndrome.Introduction
Sepsis syndrome (i.e. systemic inflammatory response
associated with infection) remains the leading cause of
mortality in ICUs, ranging from 20% in sepsis to over
60% in septic shock [1-3], despite advancements in its
management and in the understanding of its pathophysi-
ology [1,2]. In the United States, it accounts for as many* Correspondence: lawrence.c.k.sun@gmail.com; han.gung@msa.hinet.net
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reproduction in any medium, provided the ordeaths annually as myocardial infarctions [1]. Clearly,
there is an urgent need for innovative and efficacious
therapies for its treatment.
The incidence of sepsis syndrome and its prognosis
are clear [1-4], however its underlying mechanisms re-
main heavily debated [4-7]. Overwhelming inflammation
is proposed to play a crucial role in the patient’s/host’s
response to septic challenge [4,5]. This hyper-inflammatory
response involves the innate immune system [5-8], neutro-
phil and macrophage accumulation [5], cytokines secre-
tion [7,9], recruitment of T and B cells [5,10] and
formation of antibodies [11] in an attempt to eliminate
causative pathogens but this process also causesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anergy of host-defense mechanisms, rapid organ failure
and potential decline to death [12].
Previous studies [4-12] have addressed the hypothesis
that uncontrolled immune reactivity may therefore be
settled by new immunomodulatory therapeutics. Unfor-
tunately, clinical trails of immunoglobulin therapy for
patients with severe sepsis syndrome have yielded disap-
pointing results [13]. However, recent studies have
shown that mesenchymal stem cell (MSC) therapy can
down-regulate innate and adaptive immunity [14]. One
particularly intriguing finding was that apoptotic MSC
possess intense anti-inflammatory and immunomodula-
tory properties [15].
Hence, MSC therapy for various inflammatory dis-
eases/sepsis has been investigated [16-18] but reviewed
results appear to be contradictory [19]. This may partly
be explained by the heterogeneous nature of severe sep-
sis and also by the variation in tissues from which the
MSCs have been isolated; one source may have a differ-
ent capacity to immunoregulate than another. Interest-
ingly, adipose tissue-derived (AD) MSCs may have
more potent immunomodulatory capacity than bone
marrow-derived MSCs [20]. Moreover, we have recently
demonstrated that treatment with ADMSCs profoundly
reduced rodent acute lung ischemia-reperfusion injury
through highly significant suppression of oxidative stress
and inflammation [21]. MSC therapy has reportedly
been effective at reducing mortality from cecal ligation
and puncture (CLP)-induced sepsis syndrome by rebal-
ancing immune homeostasis and anti-inflammation, but
such data remains very limited [18,22]. Such potentially
promising therapeutic possibilities need further investi-
gation before any translation towards clinical application.
Accordingly, using a rodent model of sepsis-syndrome
induced by CLP, this study tested the hypothesis that 1)
healthy (H)-ADMSC therapy might significantly reduce
rat mortality and 2) apoptotic (A)-ADMSC therapy
might be superior to H-ADMSC therapy at reducing rat
mortality by attenuating the inflammatory response and
immunomodulation. The second hypothesis was basic
on the previous findings [15] and the findings of our
recent experimental study which demonstrated that
combined therapy with A-ADMSC and melatonin was
superior to the combined therapy with H-ADMSC and




All animal experimental procedures were approved by
the Institute of Animal Care and Use Committee at our
hospital and performed in accordance with the Guide
for the Care and Use of Laboratory Animals (NIHpublication No. 85-23, National Academy Press, Wash-
ington, DC, USA, revised 1996). All the technicians who
performed the bench work were blinded to the treat-
ment protocol.
Animal groups and isolation of adipose tissue for culture
of adipose-derived mesenchymal stem cells
Pathogen-free, adult male Sprague-Dawley (SD) rats
weighing 400-450 g (Charles River Technology, Bio-
LASCO Taiwan Co. Ltd., Taiwan) were randomized into
sham procedure (SP) controls (cecal exposure without
ligature and puncture), CLP + saline (3.0 cc, intra-
peritoneally at 30 min, 6 h, and 18 h after CLP), CLP +
H-ADMSC [(autologous 1.2 × 106 cells) at 30 min, 6 h,
and 18 h after CLP], CLP + A-ADMSC [(autologous
1.2 × 106 cells) at 30 min, 6 h, and 18 h after CLP; n = 16
animals per group].
There were two reasons for why the ADMSCs were
administered at 30 min, 6 h, and 18 h after CLP. First,
we have recently demonstrated that ADMSC adminis-
tration at the intervals of 30 min, 6 h, and 18 h after
acute rat kidney ischemia-reperfusion (IR) injury by
penile venous transfusion markedly attenuated acute IR-
induced kidney injury [21]. Second, we proposed that
the results of this preclinical study could provide useful
information for our future clinical application. Accord-
ingly, these intervals were initially chosen in an attempt
to mimic the clinical scheduling of antibiotics for
patients with sepsis syndrome.
Rats in groups CLP +H-ADMSC and CLP + A-
ADMSC were anesthetized with inhalational 2.0% iso-
flurane 14 days before CLP in order to harvest autolo-
gous peri-epididymal adipose tissue as we recently
reported [21]. Isolated ADMSCs were cultured in a
100 mm diameter dish with 10 mL DMEM culture
medium containing 10% FBS for 14 days. Flow cyto-
metric analysis was performed for identification of cellu-
lar characteristics (i.e., stem cell surface markers) after
cell-labeling with appropriate antibodies on day 14 of
cell cultivation prior to implantation (Table 1).
Cecal ligation and puncture (CLP), sham procedure (SP)
and measurement of tail systolic blood pressure (SBP)
Rats were anesthetized with inhalational 2.0% isoflurane
and placed supine on a warming pad at 37°C with the
abdomen shaved. Under sterile conditions, the abdom-
inal skin and muscle were opened and the cecum
exposed in all groups. In the SP control animals, the
abdomen was then closed and the animal allowed to
recover from anesthesia. In the experimental CLP groups,
the cecum was prolene suture ligated over its distal por-
tion (i.e., distal ligation) and the cecum distal to the liga-
ture was punctured twice with an 18# needle to allow
the cecal contents to be expressed intraperitoneally, as
Table 1 Flow cytometric analysis of H-ADMSC and
A-ADMSC surface markers following Day-14 cell culture
Stem cell surface markers H-ADMSC A-ADMSC* p-value
CD31+ 4.4 ± 1.9 3.1 ± 2.2 0.871
CD34+ 12.6 ± 5.6 11.2 ± 5.9 0.729
VEGF+ 29.2 ± 8.9 15.9 ± 5.7 0.027
CD45+ 13.7 ± 4.3 6.0 ± 3.3 0.022
C-kit+ 14.3 ± 4.9 8.9 ± 2.8 0.028
Sca-1+ 1.9 ± 0.7 1.6 ± 0.9 0.454
CD133+ 8.6 ± 4.2 5.7 ± 3.4 0.312
CD90+ 92.4 ± 3.7 81.4 ± 2.9 0.029
CD271+ 28.3 ± 4.2 10.1 ± 2.9 0.004
Early apoptosis (annexin V+/PI-) 1.03 ± 1.17 10.48 ± 3.67 <0.0001
Late apoptosis (annexin V+/PI+) 4.27 ± 0.59 18.18 ± 4.75 <0.0001
Data are expressed as %.
n = 8 in each experimental study.
H = healthy; A = apoptosis; ADMSC = adipose-derived mesenchymal stem cell;
VEGF = vascular endothelial growth factor.
* An additional 96 hour serum-deprived cell culture was performed for
A-ADMSCs.
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animal allowed to recover from anesthesia.
The tail SBP was measured (Kent Scientific Corpor-
ation, Model no: CODA, U.S.A) by a technician who
was blinded to the treatment protocols prior to and at
9 h and 18 h after CLP or SP (CLP/SP).
Estimation of SD Rat study group sizes
Based on previous work [24], we estimated that rat
mortality at 72 h after CLP without treatment would be
about 50%. Additionally, if clinically significant findings
were to be encountered it was calculated that at least
eight surviving rats would be required in any one group
for statistical significance to be reached at 72 h after
CLP. Accordingly, each group was assigned sixteen rats
randomly. The time of death for each rat was recorded.
Definition of healthy and apoptotic ADMSCs
Healthy ADMSCs were those cultured in normal culture
medium with adequate nutrition. Serum deprivation of
cells in vitro induces apoptosis [25]; hence, apoptotic
ADMSCs were first cultured in normal culture medium
followed by 96 hours of serum-free cell culture. The per-
centages of viable and apoptotic cells were determined
by flow cytometry using double staining of annexin V
and propidium iodide (PI); this is a simple and popular
method for the identification of apoptotic cells (i.e.
early [annexin V+/PI-] and late [annexin V+/PI+] phases
of apoptosis).
Isolation of splenocytes
Splenocytes were obtained by homogenization of the
spleen using a Tenbroeck tissue grinder followed bypassage through a 0.4-mm-pore-size cell strainer to
obtain a single cell suspension. Splenocytes were then
suspended in RPMI and speared by Ficoll-paque™ Plus
(GE Healthcare).
Flow cytometric quantification of helper T cells, cytotoxic
T cells and regulatory T cells (tregs)
Peripheral blood mononuclear cells (PBMCs) were
obtained from the tail vein using a 27# needle. PBMCs
and splenocytes (1.0 × 106 cells) were triple-stained with
FITC-anti-CD3 (BioLegend), PE-anti-CD8a (BD Bio-
science) and PE-Cy™5 anti-CD4(BD bioscience). To iden-
tify CD4+CD25+Foxp3+ Tregs, PBMCs and splenocytes
were triple-stained with Alexa FluorW 488-anti-CD25
(BioLegend), PE-anti-Foxp3 (BioLegend) and PE-Cy™5
anti-CD4 (BD bioscience) according to the manu-
facturer's protocol of Foxp3 Fix/Perm buffer set. The
numbers of CD3+CD4+ helper T cells, CD3+CD8+ cyto-
toxic T cells and CD4+CD25+Foxp3+ Tregs were anal-
yzed using flow cytometry (FC500, Beckman Coulter).
Analyses of circulating biochemical markers
Blood samples were stored at -80 oC until analyses of
tumor necrosis factor (TNF)-α, blood urea nitrogen
(BUN), creatinine, aspartate aminotransferase (AST),
alanine aminotransferase (ALT) were performed in
batches at the end of the experiment. Serum TNF-α
concentration was assessed in duplicate with a commer-
cially available ELISA kit (R&D systems, Inc. Minneap-
olis, MN). Intra-individual variability in TNF-α level was
assessed in each group. The mean intra-assay coeffi-
cients of variance were all less than 4.0%. Circulating
levels of BUN, creatinine, AST, ALT and white blood cell
(WBC) count were measured at 24 h and 72 h after
CLP/SP with standard laboratory methods.Western blot analysis of left ventricular specimens
Equal amounts (10-30 μg) of protein extracts from the
left ventricle were loaded and separated by SDS-PAGE
using 8-10% acrylamide gradients. Following electro-
phoresis, the separated proteins were transferred electro-
phoretically to a polyvinylidene difluoride (PVDF)
membrane (Amersham Biosciences). Nonspecific pro-
teins were blocked by incubating the membrane in
blocking buffer (5% nonfat dry milk in T-TBS containing
0.05% Tween 20) overnight. The membranes were incu-
bated with monoclonal antibodies against intercellular
adhesion molecule (ICAM)-1 (1: 2000, Abcam), and
polyclonal antibodies against TNF-α (1: 1000, Cell Sig-
naling), nuclear factor (NF)-κB (1: 250, Abcam), platelet-
derived growth factor (PDGF) (1:500, Abcam), matrix
metalloproteinase (MMP)-9(1:5000, Abcam), glutathione
peroxidase (GPx) (1:2000, Abcam), glutathione reductase
Chang et al. Journal of Translational Medicine 2012, 10:244 Page 4 of 14
http://www.translational-medicine.com/content/10/1/244(GR) (1:1000, Abcam), NAD(P)H quinone oxidoreductase
(NQO) 1 (1: 1000, Abcam), heme oxygenase (HO)-1 (1:
250, Abcam), Bax (1: 1000, Abcam), caspase 3 (1: 1000,
Cell Signaling), poly (ADP-ribose) polymerase (PARP)
(1: 1000, Cell Signaling), Bcl-2 (1:250, Abcam) and cyto-
chrome C (1: 2000, BD). Signals were detected with horse-
radish peroxidase (HRP)-conjugated goat anti-mouse, -rat,
or -rabbit IgG.
The Oxyblot Oxidized Protein Detection Kit was
purchased from Chemicon (S7150). The procedure of
2,4-dinitrophenylhydrazine (DNPH) derivatization was
carried out on 6 μg of protein for 15 minutes according
to the manufacturer’s instructions. One-dimensional
electrophoresis was carried out on 12% SDS/polyacryl-
amide gel after DNPH derivatization. Proteins were
transferred to nitrocellulose membranes which were
then incubated in the primary antibody solution (anti-
DNP 1: 150) for two hours, followed by incubation with
the second antibody solution (1:300) for one hour at
room temperature. The washing procedure was repeated
eight times within 40 minutes.
Immunoreactive bands were visualized by enhanced
chemiluminescence (ECL; Amersham Biosciences), which
was then exposed to Biomax L film (Kodak). For quantifi-
cation, ECL signals were digitized using Labwork software
(UVP). For oxyblot protein analysis, a standard control
was loaded on each gel.Statistical analyses
Quantitative data are expressed as mean ± SD. Statistical
analysis was performed by ANOVA followed by Bonfer-
roni multiple-comparison post hoc test. The survival
was estimated using the Kaplan–Meier method, followed
by comparing the statistical differences between various
subgroups using the nonparametric linear log-rank test. All
analyses were conducted using SAS statistical software for
Windows version 8.2 (SAS institute, Cary, NC). A prob-
ability value <0.05 was considered statistically significant.Figure 1 Rat survival 72 h after cecal ligation and puncture
(CLP) or sham procedure (SP). A) By 72 h after the CLP procedure,
the survival rate of groups CLP and CLP + H-ADMSC were
significantly lower than in groups SP and CLP + A-ADMSC (all
p values < 0.05) but it showed no difference between groups CLP
and CLP + H-ADMSC (p = p = 0.289) or between groups SP and
CLP + A-ADMSC (p = 1.0). * vs. other bars with different symbols,
p < 0.001. All statistical analyses performed using one-way ANOVA
followed by Bonferroni multiple comparison post hoc test. Symbols
(*, †) indicating statistical significance (at 0.05 level). B) Kaplan-Meyer
analysis comparing survival amongst the four groups, demonstrating
that 72 h cumulative mortality was significantly higher in the
CLP + H-ADMSC group and untreated CLP group than in SP controls
and A-ADMSC group (p < 0.001). There were no significant survival
differences between groups SP and CLP + A-ADMSC (p = 1.0), or
between groups CLP and CLP + H-ADMSC (p = 0.289). H-ADMSCs =
healthy adipose-derived mesenchymal stem cells; A-ADMSCs =
apoptotic adipose-derived mesenchymal stem cells.Results
Flow cytometric analysis of H-ADMSC and A-ADMSC
surface markers following Day-14 cell culture
Flow cytometric analysis revealed that stem cell (CD45+,
C-kit+, CD90+, CD271+) and vascular endothelial cell
[vascular endothelial growth factor (VEGF)] surface mar-
kers were significantly lower in A-ADMSCs than in H-
ADMSCs after 14-day cell culture (with the additional
96 h starvation for A-ADMSCs) (Table 1). However, the
other stem cell (Sca-1+, CD133+) and endothelial pro-
genitor cell (CD31+, CD34+) surface markers did not
differ between these two groups (Table 1). Of import-
ance, both early and late cellular apoptosis were signifi-
cantly higher in A-ADMSCs than in H-ADMSCs.Rat mortality rate 72 hours after CLP
Unexpectedly, the mortality rate was notably higher in
CLP animals treated with H-ADMSCs [mortality 62.5%
(10/16)] than CLP animals without treatment [mortality
37.5% (6/16)] but this difference did not reach statistical
significance (p = 0.289) (Figure 1A). Mortality rate in
CLP animals treated with A-ADMSC [mortality 6.25%
(1/16)] and in the SP control (mortality 0%) was similar
(Figure 1B). Interestingly, the highest incidence of deaths
in groups 2 and 3 occurred within 16 h and 24 h after
CLP. Of importance, mortality was significantly higher
in groups CLP and CLP + H-ADMSC than in groups SP
and CLP + A-ADMSC (p < 0.04).
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The SBP was similar amongst animals in the four groups
at 0 h and at 9 h after CLP/SP (Figure 2, A and B). By
18 h, however, SBP was significantly lower in CLP +
H-ADMSC group than in the other groups, significantly
lower in CLP group than in groups SP and CLP +A-
ADMSC, and similar in groups SP and CLP +A-ADMSC
(Figure 2C). Additionally, the SBP at 18 h was signifi-
cantly lower amongst the animals that ultimately died
compared with those that ultimately survived (Figure 2D).
Laboratory findings at 24 h and 72 h after CLP/SP
By 24 h after CLP/SP, serum ALT, BUN, creatinine and
WBC count did not differ between groups (Table 2).
However, serum AST was significantly higher in groups
CLP and CLP + H-ADMSC than in groups SP and CLP
+ A-ADMSC, significantly higher in group CLP + A-
ADMSC than in group SP, and not significantly different
between groups CLP and CLP +H-ADMSC (Table 2).
At 72 h, serum ALT remained similar between the four
groups. However, AST level was significantly higher
in group CLP + H-ADMSC than the other groups,
significantly higher in group CLP than in groups SP
and CLP + A-ADMSC, and significantly higher in group
CLP + A-ADMSC than in group SP (Table 2). BUN
levels were similar in groups CLP, CLP +H-ADMSC and
CLP + A-ADMSC, but significantly lower in group SP
than the other groups. Creatinine was significantly
higher in groups CLP and CLP +H-ADMSC than in
groups SP and CLP + A-ADMSC but it did not differFigure 2 Time course of systolic blood pressure (SBP) among the anim
sham procedure (SP). A) and B) The SBP at 0 h and at 9 h after CLP/SP w
* vs. other bars with different symbols, p < 0.001. D) Comparing the SBP at
and the animals that ultimately died. * vs. survival group, p < 0.0001. All sta
multiple comparison post hoc test. Symbols (*, †, ‡) indicating significance
sham procedure; H-ADMSCs = healthy adipose-derived mesenchymal stembetween groups CLP and CLP + H-ADMSC or between
groups SP and CLP + A-ADMSC. The WBC count was
significantly highest in group CLP, significantly higher in
groups CLP +H-ADMSC and CLP + A-ADMSC than
in group SP, and not significantly different in groups
CLP + H-ADMSC and CLP + A-ADMSC (Table 2).
Serial changes of circulating tumor necrosis factor-alpha
(TNF-α) levels after CLP/SP
Levels of serum TNF-α, an index of acute inflammation, were
similar amongst the groups before CLP/SP (Figure 3A).
By 6 h after CLP/SP, however, serum TNF-α was signifi-
cantly higher in groups CLP and CLP +H-ADMSC than
in groups SP and CLP + A-ADMSC, significantly higher
in group CLP +A-ADMSC than in group SP, and
not significantly different between groups CLP and
CLP +H-ADMSC (Figure 3B). By 24 h, TNF-α was
significantly higher in group CLP +H-ADMSC than in the
other groups, significantly higher in groups CLP and CLP
+A-ADMSC than in group SP, and not statistically differ-
ent in groups CLP and CLP +A-ADMSC (Figure 3C). By
72 h, the differences in this parameter between groups
were as they were at the 6 h timepoint, although the actual
serum levels were generally reduced in groups CLP, CLP +
H-ADMSC and CLP +A-ADMSC (Figure 3D).
The immune reactivity at circulation and spleen at 72 h
after CLP/SP procedure
To assess the acute immune response, circulating and
splenic levels of CD3+/CD4+ helper T cells, CD3+/CD8+als prior to and after cecal ligation and puncture (CLP) or
ere similar amongst the four groups. C) Illustrating the SBP at 24 h.
24 hour after CLP/SP between the animals that ultimately survived
tistical analyses utilized one-way ANOVA, followed by Bonferroni
(at 0.05 level). CLP = cecal ligation and puncture; Normal indicates
cells; A-ADMSCs = apoptotic adipose-derived mesenchymal stem cells.
Table 2 Hematologic and biochemical studies among the four groups
Variables SP CLP CLP +H-ADMSC CLP + A-ADMSC p-value
At 24 hour
AST 57 ± 7.1a 153.7 ± 14.1b 160.9 ± 27.5b 126.1 ± 20.9c <0.001
ALT 31.9 ± 6.7 46.1 ± 5.1 46.9 ± 18.8 35.3 ± 11.5 0.06
BUN 20.3 ± 2.4 21.8 ± 6.9 22.1 ± 6.3 23.4 ± 9.3 0.849
Creatinine 0.51 ± 0.12 0.77 ± 0.15 0.74 ± 0.25 0.66 ± 0.14 0.051
WBC count 8.1 ± 2.0 4.9 ± 2.6 7.7 ± 2.5 6.8 ± 1.4 0.057
At 72 hour
AST 46.1 ± 11.1a 106.6 ± 12.4b 134 ± 23.4c 81.6 ± 17.1d <0.001
ALT 25 ± 5.1 34.6 ± 10.1 36 ± 7.6 24.7 ± 14 0.06
BUN 16.7 ± 1.9a 28.8 ± 6.5b 28.3 ± 14.2b 25 ± 5.9b 0.018
Creatinine 0.5 ± 0.07a 0.78 ± 0.14b 0.83 ± 0.17b 0.61 ± 0.11a <0.001
WBC count 7.7 ± 1.9a 12.6 ± 2.8b 9.2 ± 3.1c 9.5 ± 2.3c 0.016
Data are expressed as means ± SD.
AST = aspartate aminotransferase; ALT = alanine aminotransferase; BUN = blood urea nitrogen; WBC = white blood cell count.
SP = sham procedure; CLP = cecal ligation and puncture; H-ADMSC = healthy adipose-derived mesenchymal stem cells; A-ADMSCs = apoptotic adipose-derived
mesenchymal stem cells.
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measured 72 h after CLP/SP. Surprisingly, there were
significantly higher circulating levels of helper and cyto-
toxic T cells in group CLP +H-ADMSC than in the other
groups, significantly higher levels in group CLP than in
groups SP and CLP + A-ADMSC, and significantly
higher levels in group CLP +A-ADMSC than in group
SP (Figure 4, A and C). Levels of helper and cytotoxic
T cells in spleen were higher in groups CLP and CLP +Figure 3 Serial changes of circulating levels of tumor necrotic factor
four groups prior to CLP/SP. B) Circulating TNF-α levels amongst the four g
p < 0.0001. C) Circulating TNF-α levels amongst the four groups at 24 h aft
D) Circulating TNF-α levels amongst the four groups at 72 h after CLP/SP. *
analyses utilized one-way ANOVA, followed by Bonferroni multiple compar
level). CLP = cecal ligation and puncture; Normal indicates sham procedure
A-ADMSCs = apoptotic adipose-derived mesenchymal stem cells.H-ADMSC than in groups SP and CLP + A-ADMSC,
higher in group CLP +H-ADMSC than in group SP, and
similar in groups CLP and CLP +H-ADMSC (Figure 4B
and D). Furthermore, the circulating and splenic levels of
Tregs, an index of immune down-regulation, were sig-
nificantly higher in groups CLP and CLP +H-ADMSC
than in groups SP and CLP + A-ADMSC; levels between
groups CLP and CLP +H-ADMSC were not significantly
different, nor were they statistically different between(TNF)-α. A) Circulating TNF-α levels did not differ amongst the
roups at 6 h after CLP/SP. * vs. other bars with different symbols,
er CLP/SP. * vs. other bars with different symbols, p < 0.0001.
vs. other bars with different symbols, p < 0.001. All statistical
ison post hoc test. Symbols (*, †, ‡) indicating significance (at 0.05
; H-ADMSCs = healthy adipose-derived mesenchymal stem cells;
Figure 4 Circulating and splenic levels of T lymphocytes at 72 h after CLP/SP. A) Circulating levels of CD3+/CD4+ cells (helper T cells).
* vs. other bars with different symbols, p < 0.001. B) Splenic levels of CD3+/CD4+ cells. * vs. other bars with different symbols, p < 0.001. C) Circulating
levels of CD3+/CD8+ cells (cytotoxic T cells). * vs. other bars with different symbols, p < 0.001. D) Splenic levels of CD3+/CD8+ cells. * vs. other bars
with different symbols, p < 0.001. E) Circulating levels of CD4 + CD25 + Foxp3+ cells (Treg cells). * vs. other bars with different symbols, p < 0.001.
F) Splenic levels of Treg cells. * vs. other bars with different symbols, p < 0.001. All statistical analyses used one-way ANOVA, followed by Bonferroni
multiple comparison post hoc test. Symbols (*, †, ‡, §) indicating significance (at 0.05 level). CLP = cecal ligation and puncture; Normal indicates sham
procedure; H-ADMSCs = healthy adipose-derived mesenchymal stem cells; A-ADMSCs = apoptotic adipose-derived mesenchymal stem cells.
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importance, the levels of these biomarkers were signifi-
cantly lower in the peripheral circulation than in spleen.
Early or late mononuclear cell (MNC) apoptosis in the
circulation at 72 h after CLP/SP
Flow cytometry demonstrated that early apoptosis of cir-
culating MNCs was highest in group CLP, significantly
higher in group CLP +H-ADMSC than in groups SP
and CLP +A-ADMSC and significantly higher in group
CLP +A-ADMSC than in group SP (Figure 5A). Late
apoptosis of MNCs in the peripheral circulation exhibited
an identical pattern, although the incidence of late apop-
tosis was lower than that of early apoptosis (Figure 5B).
The ratio of heart, lung and kidney weight to body
weight (BW) and arterial oxygen saturation (O2 sat, %)
72 hrs after CLP/SP
The ratio of heart weight to BW (Figure 6A) and kidney
weight to BW (Figure 6B) at 72 h was similar amongstthe four groups. The ratio of lung weight to BW, how-
ever, was significantly higher in groups CLP and CLP +
H-ADMSC than in groups SP and CLP + A-ADMSC at
72 h after CLP/SP (Figure 6C); this parameter did not
differ between groups CLP and CLP + H-ADMSC or
between groups SP and CLP + A-ADMSC.
Arterial O2 sat (%) was lower in group CLP +H-
ADMSC than in the other groups, significantly lower in
group CLP than in groups SP and CLP + A-ADMSC,
and significantly lower in group CLP + A-ADMSC than
in group SP at 72 h after CLP/SP (Figure 6D).
Western blot analyses of inflammatory biomarkers in left
ventricular (LV) myocardium 72 h after CLP/SP
The protein expressions of TNF-α, MMP-9, NF-κB,
three indices of inflammation, and oxidized protein, an
indicator of oxidative stress, were significantly higher in
group CLP +H-ADMSC than in groups SP, CLP and
CLP +A-ADMSC, significantly higher in group CLP than
in groups SP and CLP +A-ADMSC, and significantly
Figure 5 Circulating level of mononuclear cell apoptosis at
72 h after the CLP/SP. A) Early apoptosis. * vs. other bars with
different symbols, p < 0.0001. B) Late apoptosis. * vs. other bars with
different symbols, p < 0.0001. All statistical analyses used one-way
ANOVA, followed by Bonferroni multiple comparison post hoc
test. Symbols (*, †, ‡, §) indicating significance (at 0.05 level).
CLP = cecal ligation and puncture; Normal indicates sham procedure;
H-ADMSCs = healthy adipose-derived mesenchymal stem cells;
A-ADMSCs = apoptotic adipose-derived mesenchymal stem cells.
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(Figure 7A to C, E and F). Protein expression of ICAM-
1, another inflammatory biomarker, was significantly
higher in groups CLP and CLP + A-ADMSC than in
groups SP and CLP + A-ADMSC, and significantly
higher in group CLP +A-ADMSC than in group SP; its
expression in groups CLP and CLP +H-ADMSC was
similar (Figure 7D).
Western blot results of apoptotic biomarkers in left
ventricular (LV) myocardium at 72 h after CLP/SP
Protein expression of mitochondrial Bax (i.e., active
form), an indicator of cellular apoptosis, was significantly
higher in groups CLP and CLP +H-ADMSC than in
groups SP and CLP + A-ADMSC; no statistical differ-
ences were noted between groups CLP and CLP +H-
ADMSC or between groups SP and CLP + A-ADMSC
(Figure 8A). Additionally, protein expressions of cleaved
(active) caspase 3 and PARP, two other indicators of cel-
lular apoptosis, were highest in group CLP + H-ADMSC,significantly higher in group CLP than in groups SP
and CLP + A-ADMSC, and significantly higher in group
CLP + A-ADMSC than in group SP (Figure 8B and C).
Conversely, protein expression of Bcl-2, an indicator of
anti-apoptosis, was lowest in group CLP + H-ADMSC,
significantly lower in group CLP than in groups SP
and CLP + A-ADMSC, and significantly lower in group
CLP + A-ADMSC than in group SP (Figure 8D).
Western blot results of anti-oxidant and
mitochondrial-preservation biomarkers in left
ventricular (LV) myocardium at 72 h after CLP/SP
Protein expressions of GR, GPx, HO-1, and NQO 1, four
indices of anti-oxidants, were significantly higher in
group CLP + A-ADMSC than the other groups, signifi-
cantly higher in groups CLP and CLP +H-ADMSC than
in group SP, and statistically similar in groups CLP and
CLP + H-ADMSC (Figure 9A-D). Protein expression
of cytochrome C at mitochondrial level, an indicator
of mitochondrial preservation in LV myocardium, was
significantly higher in group SP than the other groups,
significantly higher in group CLP + A-ADMSC than
groups CLP and CLP +H-ADMSC, and significantly
higher in group CLP than in group CLP +H-ADMSC
(Figure 9F). However, the expression of this biomarker
at cytosolic level, an index of mitochondrial damage,
exhibited a reversed pattern (Figure 9E).Discussion
This study, which investigated the impact of AMDSC
administrations at three time intervals (i.e. at 0.5, 6 and
18 h) on sepsis syndrome, yielded several striking obser-
vations. First, unexpectedly, the circulating levels of
TNF-α were notably higher in animals with H-ADMSC
treatment than in animals without H-ADMSC treatment
at 24 h and 72 h after CLP. However, at the same time
intervals, the levels of this biomarker were remarkably
reversed in those animals after A-ADMSC treatment.
Second, surprisingly, the numbers of helper T cells, cyto-
toxic T cells and Tregs in both peripheral blood and
spleen were identically increased in animals with and
without H-ADSMC therapy and yet were significantly
reduced after A-ADMSC therapy. Third, more sur-
prisingly, mortality rate was relatively higher in animals
receiving H-ADMSC therapy than in animals without
H-ADMSC therapy. However, mortality was markedly
reduced in animals after A-ADMSC therapy. These find-
ings implicate that A-ADMSCs represent an endogenous
therapeutic strategy that may be possible to enhance for
maximum clinical benefit.
Many studies have shown that MSCs display multiple
beneficial properties through their capacity for hom-
ing [26,27], angiogenesis, attenuating the inflammatory
Figure 6 Ratio of heart weight (HW), kidney weight (KW) and lung weight (LW) to the body weight (BW) at 72 h after CLP/SP. A)
The ratio of HW to BW at 72 h after CLP/SP did not differ between the four groups. B) The ratio of KW to BW at 72 h after CLP/SP did not
differ between the four groups. C) The ratio of LW to BW at 72 h after CLP/SP, respectively. * vs. other bars with different symbols, p < 0.001.
D) The arterial oxygen saturation (%) at 72 h after CLP/SP. * vs. other bars with different symbols, p < 0.001. All statistical analyses used one-way
ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡, §) indicating significance (at 0.05 level). CLP = cecal ligation
and puncture; Normal indicates sham procedure; H-ADMSCs = healthy adipose-derived mesenchymal stem cells; A-ADMSCs = apoptotic
adipose-derived mesenchymal stem cells.
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and promoting tissue regeneration [21,27]. Additionally,
studies have also demonstrated that MSCs may be useful
therapeutic adjuncts for reducing mortality in experi-
mental models of sepsis syndrome by inhibiting the
inflammatory and immunoregulatory response [18,22].
Surprisingly, the current study revealed that the mortal-
ity rate was notably higher in CLP animals that received
H-ADMSC therapy than in CLP animals without treat-
ment, which does not support the findings of others
[18,22]. Conversely, however, mortality following CLP
was significantly reduced by A-ADMSC therapy. In this
way, our findings corroborated those of previous studies
[18,22]. Our observations may, therefore, suggest that
the immunomodulatory capacity and anti-inflammatory
property that is more potent in A-ADMSCs than in H-
ADMSCs played the crucial role for reducing sepsis-
induced mortality. Our suggestion is supported by our
following findings. Firstly, circulating TNF-α level was
identically increased at the 6 h timepoint after CLP in
H-ADMSC treated and untreated animals, becoming
significantly increased in H-ADMSC treated animals at
24 and 72 h compared with untreated animals. However,
the circulating TNF-α levels were significantly reversed
after A-ADMSC treatment. Secondly, compared with SP
controls, the circulating and splenic levels of helper
T cells, cytotoxic T cells and Tregs were significantlyhigher in untreated CLP animals than in animals with
A-ADMSC therapy at 72 h after CLP, and yet these
levels were even higher in group CLP +H-ADMSC
where animals were treated with H-ADMSC following
CLP. These findings might, at least in part, support
the findings that the mortality rate was notably higher
in animals with H-ADMSC treatment than in those
animals without treatment. These findings could also
explain why the mortality rate was remarkably reduced
in animals with A-ADMSC therapy than in animals with
no treatment or with H-ADMSC therapy.
Major organs are frequently damaged by sepsis syn-
drome [1-4]. Consistent with previous reports [1-4], our
results demonstrated that liver and renal functions were
significantly impaired in CLP animals compared with SP
controls. Additionally, arterial oxygen saturation, an
index of lung function, was significantly lower whilst
lung weight to body weight ratio was significantly
increased (an index of lung damage) in CLP animals than
in SP controls. Furthermore, of particular importance
was that these functional organ damages were more
severe in animals receiving H-ADMSC therapy than in
those who underwent CLP without treatment. How-
ever, these functional damages were notably reversed
after A-ADMSC therapy. Collectively, these findings
could also partially explain why mortality was higher in
the CLP group that was treated with H-ADMSC than in
Figure 7 Protein expressions of inflammatory and oxidative stress biomarkers of left ventricular myocardium at 72 h after CLP/SP.
A, B and C) The protein expressions of tumor necrotic factor (TNF)-α (A), matrix metalloproteinase (MMP)-9 (B) and nuclear factor (NF)-κB
(C) exhibited an identical pattern amongst the four groups. * vs. other bars with different symbols, p < 0.0001. D) The protein expression of
intercellular adhesion molecule (ICAM)-1. * vs. other bars with different symbols, p < 0.0001. E & F) Expression of protein carbonyls (i.e., oxidized
protein), an oxidative index, in the four groups of animals [Note: Right lane and left lane shown on left lower panel (E) representing control
oxidized molecular protein standard and protein molecular weight marker, respectively]. DNP = 1-3 dinitrophenylhydrazone. * vs. other bars
with different symbols, p < 0.0001. a = SP control; b = CLP; c = CLP + H-ADMSCs; d = CLP + A-ADMSCs. All statistical analyses used one-way
ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡, §) indicating significance (at 0.05 level). CLP = cecal ligation
and puncture; Normal indicates sham procedure; H-ADMSCs = healthy adipose-derived mesenchymal stem cells; A-ADMSCs = apoptotic
adipose-derived mesenchymal stem cells.
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in the A-ADMSC treated CLP group. Recently, studies
have shown that MSC therapy attenuated organ injury
induced by endotoxemia [16,28]. In this way, the results
of A-ADMSC therapy were consistent with these recent
studies [16,28].Apart from evaluating the impact of ADMSC therapy
on protecting pulmonary and renal function, the current
study also considered the molecular-cellular levels in left
ventricular myocardium at 72 h after CLP/SP. Anatom-
ically, the ratio of heart weight to body weight did not
differ among the four groups. However, the protein
Figure 8 Protein expressions of apoptotic and anti-apoptotic biomarkers of left ventricular myocardium at 72 h after CLP/SP.
A, B and C) The protein expressions of mitochondrial Bax (A), cleaved casapse 3 (C-Csp 3) (B) and cleaved poly (ADP-ribose) polymerase
(C-PARP) exhibited a similar pattern amongst the four groups. * vs. other bars with different symbols, p < 0.001. D) The protein expression of
Bcl-2. * vs. other bars with different symbols, p < 0.001. All statistical analyses used one-way ANOVA, followed by Bonferroni multiple comparison
post hoc test. Symbols (*, †, ‡, §) indicating significance (at 0.05 level). CLP = cecal ligation and puncture; Normal indicates sham procedure;
H-ADMSCs = healthy adipose-derived mesenchymal stem cells; A-ADMSCs = apoptotic adipose-derived mesenchymal stem cells.
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stress were substantially higher in animals with than in
animals without H-ADMSC therapy. These findings
imply that H-ADMSC therapy did not enhance anti-
inflammation either in the circulation or in the specific
tissues/major organs in setting of sepsis syndrome. In
contrast, A-ADMSC therapy markedly reduced the
protein expressions of these inflammatory biomarkers.
One recent study has also revealed that MSC therapy
significantly reduced endotoxin elicited inflammatory
biomarkers in left ventricular myocardium [16]. Our
findings of A-ADMSC treatment therefore corroborate
those of others [16] but this is also reinforced by our per-
ipheral circulating measurements that demonstrated A-
ADMSC therapy significantly enhanced anti-inflammation
in sepsis syndrome. Besides, the protein expressions
of antioxidants and mitochondrial preservation were
remarkably lower in animals with and without H-
ADMSC treatment compared with those animals that
received A-ADMSC treatment. These findings highlight that
A-ADMSC therapy not only enhanced anti-inflammatory
capability but also enriched the anti-oxidant ability in
the setting of sepsis syndrome.Sepsis induced apoptosis has been well recognized in
previous studies [28]. In the current study, one essential
finding was that the number of circulating apoptotic
mononuclear cells (i.e., early and late apoptosis) was
substantially increased at 72 h in animals with or with-
out H-ADMSC therapy after CLP than in SP controls.
However, these biomarkers were substantially decreased
in animals after A-ADMSC treatment. Similarly, the
protein expressions of apoptotic biomarkers in left
ventricular myocardium exhibited an identical pattern
of circulating mononuclear cell apoptosis amongst the
four groups 72 h after CLP/SP. Our findings, in addition
to strengthening the findings of others [28], suggest that
A-ADMSC therapy significantly prevented cellular apop-
tosis and ultimately protected the organ/tissue from
sepsis-induced damage.
We remain uncertain why there was a discrepancy
between our results of H-ADMSC therapy (ineffective in
reducing mortality) and A-ADMSC therapy (effective in
reducing mortality) and the findings of others in the set-
ting of sepsis with MSC therapy (reportedly effective
in reducing mortality) [18,22]. We propose that the fol-
lowing reasons could explain the discrepancy. First, we
Figure 9 Protein expressions of anti-oxidant and mitochondrial preservation biomarkers of left ventricular myocardium at 72 h after
CLP/SP. A, B, C and D) The protein expressions of glutathione reductase (GR) (A) glutathione peroxidase (GPx) (B), heme oxygenase (HO)-1
(C) and NAD(P)H quinone oxidoreductase (NQO) 1 (D) displayed an identical pattern amongst the four groups. * vs. other bars with different
symbols, p < 0.001. E & F) Protein expression of cytosolic (E) and mitochondrial (F) cytochrome C (Cyt C). * vs. other bars with different symbols,
p < 0.001. All statistical analyses used one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡, §) indicating
significance (at 0.05 level). CLP = cecal ligation and puncture; Normal indicates sham control; H-ADMSCs = healthy adipose-derived mesenchymal
stem cells; A-ADMSCs = apoptotic adipose-derived mesenchymal stem cells.
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3rd dosage, might elicit a hyper-reactive immune re-
sponse that mimicked a delayed hypersensitivity rather
than immune desensitization. This suggestion is sup-
ported by our findings that the numbers of helper T
cells, cytotoxic T cells and Tregs were substantially
increased in both circulating and spleen levels at 72 h
after CLP. This may lend some explanation to why the
majority of the rats died more than 18 h after CLP. Sec-
ond, previous studies have shown that more that 5%-25% of the prepared MSCs exhibited cellular apoptosis
before they were injected or implanted into an ischemic
area [15]. A further proportion of healthy injected living
cells are susceptible to apoptosis within ischemic organ/
tissue due to exposure to various proapoptotic or
cytotoxic factors in an ischemic environment [15,29].
Apoptotic rather than healthy stem cells have been
emphasized to possess a unique property of immune
dampening by down-regulating innate and adaptive
immunity, deactivating macrophages and dendritic cells,
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metric analyses showed that early apoptosis was less
than 1.1% and late apoptosis was less than 4.5% in H-
ADMSCs. However, more than 10% of early apoptosis
and more than 18% of late apoptosis were found in A-
ADMSCs after 96 h serum-deprived cell culture. These
may explain the differing immunologic homeostasis, tol-
erance and mortality between animals with H-ADMSC
therapy and animals with A-ADMSC therapy in the
present study.
Study limitations
This study is limited by the following factors. First,
although the numbers of in vitro apoptosis of both H-
ADMSCs and A-ADMSCs were estimated, we did not
measure the time course of circulating numbers of apop-
totic H-ADMSCs or A-ADMSCs. Therefore, we could
not provide the incidence of apoptosis in vivo for these
stem cells. Second, the study period was only 72 h,
therefore we have not yet provided the long-term results
of animals after ADMSC therapy in the setting of sepsis
syndrome. Third, the study did not extensively surveyed
the serial changes of circulating inflammatory cytokines/
chemokines that might provide more useful information
for predicting the prognostic outcome after sepsis syn-
drome. Finally, the H-ADMSCs were retained in 3 cc
fetal bovine serum whereas the A-ADMSCs were
retained in 3 cc serum-free culture medium prior to
treat the animals. We remain uncertain if the fetal
bovine serum also played some certain role on eliciting
the immune response during the treatment course.
Conclusions
A-ADMSC therapy appears superior to H-ADMSC ther-
apy for preserving organ function and reducing mortality
in rat sepsis syndrome. This indicates a potentially
important role for A-ADMSC therapy for sepsis syndrome.
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